Novartis India Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Novartis India Ltd.
Scrip takes a look at the key trends that could play out in 2021 to shape the trajectory of Indian drug makers, including evolving dynamics in the US under a new president. Thorny India-China relations will add a layer of complexity, while firms may also want to look beyond the chief information officers as they ramp up digital engagement.
OPPI director general and ex-MSD India chief outlines how pharma in India is ensuring medicines reach patients amid COVID-19, working closely with various stakeholders. De-risking the supply chain and up-skilling sales forces in view of widespread digital engagement are among the key issues firms are addressing.
White House directive aimed at reducing dependence on foreign manufacturers for essential medicines and a seemingly more aggressive stance towards site inspections could signal a worrying emerging trend for India pharma. But it also needs to be viewed through the prism of the upcoming US elections and trade tensions with China amid the pandemic.
Novartis India chief outlines how the company is navigating the challenging business environment amid the coronavirus pandemic, including for its for-profit social business. Digital solutions are a key part of these efforts and the executive offers advice for those struggling to balance the work-life mix in these testing times.